Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial

2020 ◽  
Author(s):  
F Heitz ◽  
G Valabrega ◽  
B Pothuri ◽  
A Oaknin ◽  
W Graybill ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Older Patients ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety

scholarly journals 347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial

2020 ◽  
Author(s):  
Hanna Dahlstrand ◽  
Bhavana Pothuri ◽  
Whitney Graybill ◽  
Thibault de La Motte Rouge ◽  
Colleen Mccormick ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Older Patients ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety

Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5529-5529 ◽  
Author(s):  
Susan M. Domchek ◽  
Ronnie Shapira-Frommer ◽  
Rita K. Schmutzler ◽  
M. William Audeh ◽  
Michael Friedlander ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Clinical efficacy and safety of apatinib combined with oral VP-16 for the treatment of advanced ovarian cancer: Preliminary evaluation of a clinical drug regimen

2020 ◽  
Vol 6 (2) ◽  
pp. 209-213
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Clinical Efficacy ◽  
Advanced Ovarian Cancer ◽  
Symptomatic Treatment ◽  
Drug Regimen ◽  
Preliminary Evaluation ◽  
Efficacy And Safety ◽  
Advanced Ovarian Carcinoma ◽  
Hand Foot Syndrome

To investigate the clinical efficacy and safety of apatinib in combination with oral VP-16 for the treatment of chemotherapy-resistant advanced ovarian carcinoma. Twenty-seven advanced ovarian carcinoma patients were treated with oral VP-16 chemotherapy combined with oral apatinib mesylate (500 mg/d). CA125, VEGF, and CEA were examined every 3-4 weeks, and tumour changes were monitored by CT every 8-12 weeks. PFS was obtained by follow-up after discharge. For all patients, the ORR (including CR and PR) was 25.0%, and the DCR (including CR, PR and SD) was 75.0%. CEA and CA199 significantly decreased (p<0.05), but the decrease in VEGF was not significant. The average PFS was 5.13 months. The ECOG score had a significant effect on PFS (p<0.05), while there were no significant differences in PFS based on age (p=0.394). The main side effects of this regimen were hypertension, proteinuria, hand-foot syndrome and myelosuppression, which were tolerated by patients after active symptomatic treatment. Apatinib combined with oral VP-16 is an effective regimen for the treatment of chemotherapy-resistant advanced ovarian cancer. This combination therapy should be widely used in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document